drugset
drugset / Trial / NCT05866055

A Phase 1 Dose Escalation Study of VX-973 in Healthy Adults

NCT05866055 ↗

Phase 1 Completed 30 enrolled Vertex Pharmaceuticals Incorporated
RandomizedSequentialQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of VX-973 in healthy participants.

Timeline

Start
2023-05-10
Primary completion
2024-04-04
Completion
2024-04-04

Drugs

EvaluationDrugModalityDoseRoute
Subject VX-973 Unknown — Oral
Background Midazolam Small molecule 2 mg Oral

Indications

No indication recorded.